Healthcare Industry News: Beckman Coulter
News Release - November 19, 2007
Beckman Coulter to Acquire Flow Cytometry Instrumentation Business From DakoHighly-Regarded Research Flow Cytometry Portfolio Targeted at Fast Growing Market Segment
FULLERTON, Calif., and GLOSTRUP, Denmark, Nov. 19 (HSMN NewsFeed) -- Beckman Coulter, Inc. (NYSE: BEC ), a leading developer of products that simplify and automate complex biomedical testing, and Dako Denmark A/S, a world leader in cancer diagnostics, announced today that Beckman Coulter will acquire Dako's research flow cytometry instrumentation business, which is based in Fort Collins, Colorado. Financial terms were not disclosed.
Scott Garrett, Beckman Coulter's president and chief executive officer, said, "We are enthusiastic about the opportunity to add Dako's MoFlo XDP high-performance sorter, the gold standard for cell sorting, and the highly capable nine-color CyAn research flow cytometer to our existing portfolio of cytometry instruments. This transaction allows us to offer a more comprehensive range of research solutions to our customers."
Dako's president and CEO, Patrik Dahlen, said, "This action reinforces our strategic intent to create a more focused business in anatomic pathology and tissue-based cancer diagnostics. We believe our flow cytometry instrumentation products are an excellent match for Beckman Coulter and will achieve even greater success when combined with the company's existing flow cytometry infrastructure and reputation for quality, service and support."
Dako's flow cytometry instrument business workforce of almost 200 people includes sales, marketing, research, manufacturing and administrative personnel. Flow cytometry is used to analyze cells in blood and other fluids for both research applications and diagnosis of diseases such as leukemia, lymphoma and HIV.
Garrett added, "I want to welcome the talented people transferring to us from Dako. We see significant opportunities for Beckman Coulter in flow cytometry and continue to expand our investment in this fast-growing market segment."
The transaction is expected to close by the end of the year. More information about the transaction will be available during Beckman Coulter's 2007 Annual Business Review meeting on December 11. Contact Investor Relations for details.
Dako, which is headquartered in Denmark, strives to improve tissue-based cancer diagnostics focusing on the workflow in the pathology laboratory. The company develops and markets instruments, reagents and software that will reduce time from biopsy to diagnosis, improve the quality and reliability of diagnosis, and increase efficiency in the lab. For information, visit http://www.dako.com.
About Beckman Coulter, Inc.
Based in Fullerton, California, Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue consisting of supplies, test kits, service and operating-type lease payments represents more than 75 percent of the company's 2006 annual revenue of $2.53 billion. For more information, visit http://www.beckmancoulter.com.
Forward Looking Statements
This press release contains forward-looking statements, including statements regarding the contribution of the acquisition to Beckman Coulter's R&D and product development capability. These statements are based on current expectations and assumptions. Actual results could differ materially from those anticipated by these forward-looking statements as a result of a number of factors, some of which may be beyond Beckman Coulter's control. Beckman Coulter disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Source: Beckman Coulter
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.